Cosette Faces $13.27M Legal Costs After Losing to Mayne Pharma
Mayne Pharma has been awarded $13.27 million in legal costs by the Supreme Court of New South Wales after successfully defending against Cosette Pharmaceuticals’ claims tied to a terminated acquisition deal.
- Court orders Cosette to pay $13.27M legal costs
- Mayne Pharma's claims against Cosette fully upheld
- Legal costs include interest, payment terms pending
- Dispute stems from terminated Scheme Implementation Deed
- Potential impact on Mayne Pharma’s financial position
Court Awards Mayne Pharma $13.27 Million in Legal Costs
Mayne Pharma (ASX:MYX) has emerged from its legal battle with Cosette Pharmaceuticals with a significant financial win. The Supreme Court of New South Wales has ruled that Cosette must pay Mayne Pharma $13,269,328.04 in legal costs, plus interest, following the dismissal of all Cosette’s claims in a dispute over the termination of a Scheme Implementation Deed signed earlier in 2025.
The original legal proceedings, initiated by Mayne Pharma in June 2025, challenged Cosette’s purported termination of their acquisition agreement. After months of litigation, the Court sided decisively with Mayne Pharma in October 2025, rejecting Cosette’s claims and ordering them to cover Mayne Pharma’s legal expenses. The latest judgment formalises the quantum of those costs, marking a clear financial recovery for Mayne Pharma.
Background to the Dispute and Legal Proceedings
The dispute arose from Cosette’s attempt to terminate the Scheme Implementation Deed signed in February 2025, which was intended to govern Cosette’s acquisition of Mayne Pharma. Mayne Pharma responded by filing legal action to enforce the agreement and seek damages. The Court’s rulings have effectively vindicated Mayne Pharma’s position, dismissing Cosette’s termination as unjustified and ordering them to bear the legal costs.
This legal victory comes at a pivotal time for Mayne Pharma, which has recently reported a surge in cash flow and prescription growth driven by its DistributeRx launch and expanding Women’s Health portfolio. The cost recovery will provide a welcome boost to the company’s financial position, complementing its underlying business momentum documented in recent quarterly results.
Next Steps and Financial Implications
The Court is expected to issue further orders soon to finalise the interest amount payable by Cosette and set a timetable for the payment of the awarded costs. Mayne Pharma may also seek to recover additional costs related to the application for costs. While the ruling closes a significant chapter in the dispute, the possibility of appeals or further legal manoeuvres cannot be discounted at this stage.
Investors should note that this $13.27 million legal cost award will positively impact Mayne Pharma’s cash flow and earnings, potentially enhancing its balance sheet resilience. The timing and receipt of these funds, however, remain subject to court orders and Cosette’s compliance.
Mayne Pharma’s recent operational progress, including its strong launch of DistributeRx and leadership changes earlier this year, sets a backdrop of strategic renewal that this legal outcome may reinforce. The company’s ability to convert legal victories into shareholder value will be an area to watch closely in the coming months.
Mayne Pharma’s legal triumph in this high-stakes dispute underscores the complex interplay between corporate strategy and litigation in the pharmaceutical sector, where acquisition deals often hinge on finely balanced contractual terms and their enforcement.
Bottom Line?
Mayne Pharma’s $13.27 million legal cost recovery strengthens its financial footing but leaves open questions about the timing of funds and potential further legal actions.
Questions in the middle?
- Will Cosette Pharmaceuticals appeal the legal costs judgment?
- How will the legal cost recovery influence Mayne Pharma’s FY26 earnings forecasts?
- Could this legal outcome affect Mayne Pharma’s future M&A strategy?
